

## **AMENDMENTS TO THE CLAIMS**

Please amend claims 75, 91, 94, 99, and 123-124. This listing of claims replaces all previous versions and listings of claims.

### **Listing of Claims:**

1-74. **(Canceled)**

75. **(Currently amended)** A method for determining whether a subject is likely to have a colon neoplasm comprising:

- a) obtaining a biological sample from said subject; and
- b) detecting in the biological sample at least one secreted ColoUp2 polypeptide selected from the group consisting of: (i) a secreted polypeptide having an amino acid sequence at least 95% identical to SEQ ID NO: 21 ~~produced by the expression of the nucleic acid having the nucleic acid sequence of SEQ ID NO: 5~~, and (ii) a secreted polypeptide having ~~the~~ an amino acid sequence ~~of at least 95% identical to~~ SEQ ID NO: 3, wherein the presence of said at least one secreted ColoUp2 polypeptide indicates that the subject is likely to have a colon neoplasm.

76-83. **(Canceled)**

84. **(Previously presented)** The method of claim 75, wherein the biological sample is a whole blood sample or a fraction derived from blood.

85. **(Previously presented)** The method of claim 84, wherein the biological sample is selected from among blood plasma and blood serum.

86. **(Original)** The method of claim 75, wherein the biological sample is derived from the inner wall and/or lumen of the intestinal tract.

87. **(Previously presented)** The method of claim 75, wherein the biological sample is a stool sample.

88. **(Original)** The method of claim 75, wherein the biological sample is a urine sample.
89. **(Original)** The method of claim 75, wherein the polypeptide is detected by an assay that employs an antibody.
90. **(Previously presented)** The method of claim 89, wherein the assay is selected from among: an immunoprecipitation assay, a Western blot, a radioimmunoassay and an enzyme-linked immunosorbent assay (ELISA).
91. **(Currently amended)** The method of claim 89, wherein the assay comprises contacting the biological sample with an antibody that interacts with said at least secreted ColoUp2 polypeptide.
92. **(Canceled)**
93. **(Previously presented)** The method of claim 89, wherein the antibody interacts with an epitope of the amino acid sequence of SEQ ID NO: 3.
94. **(Currently amended)** The method of claim 89, wherein the antibody interacts with an epitope of ~~said the~~ the ColoUp2 polypeptide encoded by ~~produced by the expression of~~ the nucleic acid sequence set forth in SEQ ID NO: 5.
95. **(Original)** The method of claim 89, wherein the antibody is detectably labeled.
96. **(Original)** The method of claim 95, wherein the label is selected from the group consisting of an enzyme, a fluorescent substance, a chemiluminescent substance, a chromophore, a radioactive isotope and a complexing agent.
97. **(Previously presented)** The method of claim 75, further comprising determining the amount of said at least one secreted ColoUp2 polypeptide in the biological sample.
98. **(Previously presented)** The method of claim 97, wherein the method further comprises:  
(a) determining the amount of said at least one secreted ColoUp2 polypeptide in the biological sample from said subject;

(b) determining the amount of said at least one secreted ColoUp2 polypeptide in a biological sample obtained from a different, normal control subject; and

(c) comparing the amount from step (a) to the amount from step (b).

99. **(Currently amended)** The method of claim 97, wherein the method further comprises:

~~(a) determining the amount of said at least one secreted ColoUp2 polypeptide in the biological sample from said subject; and~~

~~——(b) comparing the amount from step (a) of said at least one secreted ColoUp2 polypeptide to an amount determined in a sample obtained from said subject in the past.~~

100. **(Previously presented)** The method of claim 75, wherein the colon neoplasm is a colon adenoma or a colon cancer.

101. **(Previously presented)** The method of claim 75, wherein the presence of said at least one secreted ColoUp2 polypeptide aids in determining the therapeutic protocol to be administered to a subject likely to have colon neoplasia.

102. **(Original)** The method of claim 75, wherein the subject was not previously diagnosed with colon cancer.

103. **(Canceled)**

104. **(Previously presented)** The method of claim 75, wherein the colon neoplasm is a colon adenoma.

105. **(Previously presented)** The method of claim 75, wherein the colon neoplasm is colon cancer.

106. **(Previously presented)** The method of claim 75, wherein the colon neoplasm is metastatic colon cancer.

107-122. **(Canceled)**

123. **(Currently amended)** The method of claim 75, wherein the polypeptide ~~produced by the expression of the nucleic acid sequence of SEQ ID NO: 5 is a polypeptide having~~ has the sequence of SEQ ID NO: 21.

124. **(Currently amended)** The method of claim 75, wherein the polypeptide ~~produced by the expression of the nucleic acid sequence of SEQ ID NO: 5 is a polypeptide having~~ has the sequence of SEQ ID NO: 3.

125. **(Canceled)**